More on MBRX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.80 |
|
|||
| Open | $2.90 | ||||
| 52 Wk High | $9.58 | ||||
| 52 Wk Low | $2.34 | ||||
| Day High | $2.96 | ||||
| Day Low | $2.81 | ||||
| P/E | N/A | ||||
| EPS | $-0.34 | ||||
| Volume | 379,154 | ||||
- Form 8-K Moleculin Biotech, Inc. For: Jun 05
- Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
- Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
- Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor “What This Means” Segment
- Form 8-K Moleculin Biotech, Inc. For: May 29
- Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
- Form 8-K Moleculin Biotech, Inc. For: May 26
- Form 8-K Moleculin Biotech, Inc. For: May 22
- Moleculin presents cardiac safety data for Annamycin at 2026 ASCO meeting
- Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
Entities mentioned with MBRX
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- S1 | View Related Stories »
- Roth Capital | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Show More...
